Moderna, Inc. (MRNA)
- Sector
- Health Care
- Industry
- Biotechnology
- Last price
- $216.25
- As of
Kresmion compiles this page from MRNA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Moderna, Inc. (MRNA): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-30.
See the full MRNA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MRNA on one page. Preview it with sample data, then open it live with a free account.
Preview the MRNA dossierActive signals for MRNA
- highPROBABILITY_SHIFT
Prediction market repriced: "Skin cancer vaccine BLA submitted by June 30, 2027?" moved -20pp in 24h to 57%
- mediumPROBABILITY_SHIFT
Prediction market repriced: "Skin cancer vaccine FDA approved by December 31, 2027?" moved -16pp in 24h to 50%
- highCONSENSUS_SELL
6 tracked funds reduced MRNA this 2026Q2, institutional consensus
- mediumPROBABILITY_SHIFT
Prediction market repriced: "Skin cancer vaccine FDA approved by December 31, 2027?" moved +18pp in 24h to 68%
- mediumPROBABILITY_SHIFT
Prediction market repriced: "Skin cancer vaccine FDA approved by December 31, 2027?" moved -18pp in 24h to 50%
FREE, NO ACCOUNT
Every signal on MRNA, as it fires
You are seeing 5 of 55 signals recorded on MRNA since 2026-05-05.
The five above landed across 5 days. The other 50 were recorded on 6 other days. 43 of the 55 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MRNA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 60770K107 · 2026Q2 | $503.8M | 0.36% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 60770K107 · 2026Q2 | $30.7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 60770K107 · 2026Q2 | $20.6M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 60770K107 · 2026Q2 | $1.7M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 60770K107 · 2026Q2 | $807K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MRNA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
MRNA against its peers
MRNA's operating margin of -158.1% ranks in the 12th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | MRNA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.9B USD | 3.4B USD | 26 | 20 |
| Operating margin | -158.1% | 24.7% | 12 | 20 |
| Net margin | -145.2% | 16.7% | 16 | 21 |
| Return on equity | -32.6% | 14.6% | 17 | 20 |
| P / E | n/a | 27.8x | n/a | 12 |
| 1 year | 708.7% | 29.6% | 98 | 19 |
Peers (23): REGN, VRTX, NTRA, ARGX, GILD, RVMD, ONC, AMGN, BIIB, ALNY, ROIV, RPRX, BNTX, UTHR, INCY, GMAB, INSM, ABBV, ASND, EXEL, NBIX, SMMT, BBIO. Left out: CSLLY (no annual filing), IVBXF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (MRNA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow MRNA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to MRNA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.